Synonyms: ENMD 2076 | ENMD2076
Compound class:
Synthetic organic
Comment: ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor. It inhibits a distinct profile of angiogenic tyrosine kinases in addition to the Aurora A kinase. These angiogenic targets include VEGFR, Flt3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
ENMD-2076 progressed to Phase 2 clinical evaluation for indications including ovarian clear cell cancers (NCT01914510), advanced/metastatic soft tissue sarcoma (NCT01719744) and advanced fibrolamellar carcinoma (NCT02234986). Development does not appear to have progressed further. |